The International Agency for Research on Cancer (IARC) has classified arsenic in drinking water as a group 1 carcinogen that causes skin cancer, bladder cancer, and lung cancer ([@b18-ehp0114-001293]). Substantial evidence supports the biologic plausibility that exposure to arsenic can lead to skin and bladder cancer. For example, arsenic concentrates in the skin and is known to cause nonmalignant skin lesions \[[@b23-ehp0114-001293]\], and the major pathway of excretion is in urine, giving plausibility to increased bladder cancer rates ([@b23-ehp0114-001293]). Although it is known that inhalation of arsenic may cause lung cancer, the findings of increased lung cancer mortality after ingestion in drinking water were unexpected because all other known lung carcinogens act via inhalation. However, the evidence based on multiple studies in Taiwan ([@b6-ehp0114-001293]; [@b5-ehp0114-001293], [@b7-ehp0114-001293]; [@b37-ehp0114-001293]), Chile ([@b10-ehp0114-001293]; [@b27-ehp0114-001293]), Argentina ([@b15-ehp0114-001293]), and Japan ([@b29-ehp0114-001293], [@b28-ehp0114-001293]) is sufficient to conclude that there is a causal relationship. In fact, lung cancer is the main long-term cause of death from ingesting arsenic in drinking water ([@b23-ehp0114-001293]). In region II of Chile, which includes the city of Antofagasta, overall lung cancer mortality rates for men and women were previously found to be at least 3-fold higher than for the rest of Chile ([@b27-ehp0114-001293]), and lung cancer relative risk estimates increased nearly 9-fold in those with the highest exposures ([@b10-ehp0114-001293]).

Several known lung carcinogens cause chronic nonmalignant respiratory diseases, including cigarette smoking, which causes chronic obstructive pulmonary disease (COPD); asbestos, which causes asbestosis; and silica, which causes silicosis. To date, however, relatively little attention has been given to whether or not ingestion of arsenic in drinking water causes nonmalignant pulmonary disease. The first reports of chronic respiratory symptoms came from small investigations in Antofagasta in the 1970s ([@b39-ehp0114-001293], [@b40-ehp0114-001293], [@b41-ehp0114-001293]; [@b42-ehp0114-001293]). Before 1958, the water supply in the main city of Antofagasta had an arsenic concentration of about 90 μg/L. A growing population led to supplementation of Antofagasta's water supply in the late 1950s with water from rivers with arsenic concentrations near 1,000 μg/L. Because this area is among the driest places on Earth, there are very few individual water supplies, and almost everyone drinks water from the same municipal sources. After the installation of a new treatment plant in 1971, arsenic levels in Antofagasta water dropped abruptly to about 90 μg/L and have been progressively reduced further in recent years ([@b10-ehp0114-001293]). These data are shown in [Figure 1](#f1-ehp0114-001293){ref-type="fig"}.

In a 1998 publication concerning region II, increased COPD mortality was reported for the 30- to 39-year age group ([@b27-ehp0114-001293]). Based on the time period in which mortality was assessed (1989--1993), subjects in the 30- to 39-year age group would have been *in utero* or young children at the time of the peak exposure period in Antofagasta. These results were based on a small number of cases but were later supported by findings from other arsenic-exposed regions. For example, increases in symptoms of chronic respiratory disease were found to be associated with arsenic ingestion in studies in West Bengal, India ([@b9-ehp0114-001293]; [@b11-ehp0114-001293]) and Bangladesh ([@b20-ehp0114-001293]). Recently, two studies in West Bengal involving participants with arsenic-caused skin lesions reported major deficits in pulmonary function ([@b33-ehp0114-001293]) and a 10-fold increase in prevalence of bronchiectasis identified by high-resolution computed tomography ([@b12-ehp0114-001293]).

The distinct period of high arsenic exposure in Antofagasta from 1958 through 1970 offers the opportunity to investigate the health effects of early-life arsenic exposure. In this study, we take advantage of this unique situation in order to assess adult mortality in those born during the high-exposure period who would have experienced exposure *in utero* as well as early childhood, and those born just before 1958 who would have experienced high exposure during childhood but not *in utero*.

Materials and Methods
=====================

We obtained computerized mortality data for 1989--2000 from the Ministry of Health for all 13 regions of Chile. Deaths were divided into two groups: those who were residents of Antofagasta and neighboring Mejillones, cities that have the same water source; and those who were residents in all regions of Chile other than region II, in which Antofagasta and Mejillones are located. Two birth cohorts were defined for this investigation: those born in the period 1958--1970 (probable *in utero* exposure if resident in Antofagasta/Mejillones) and those born in 1950--1957 (probable childhood exposure if born in Antofagasta/Mejillones). Causes of death were coded according to the *International Classification of Diseases, 9th Revision* (ICD-9; [@b35-ehp0114-001293]), including lung cancer (ICD-9 code 162) and chronic respiratory disease (ICD-9 codes 490, 491, 492, 494, and 496). We obtained annual estimates of the population living in Antofagasta/Mejillones in region II, and for the rest of Chile excluding region II, for 1989--2000 from the National Institute of Statistics (Instituto Nacional de Estadísticas) stratified by age and sex.

In 2000, the most recent year for which mortality data are available, the oldest persons in the first birth cohort born in the period 1950--1957 would have been 50 years old. We therefore calculated standardized mortality ratios (SMRs) for men and women separately, 30--49 years of age, using 10-year age groups (30--39 and 40--49 years) for standardization. Mortality in younger ages was not included because death from lung cancer or chronic respiratory disease is extremely rare in individuals \< 30 years of age. We calculated SMRs as the observed number of deaths divided by the expected number of deaths, using all regions in Chile outside of region II as the referent population. We estimated SMRs for lung cancer, for bronchiectasis, and for other COPD causes of death excluding bronchiectasis, and also for all other causes of death excluding lung cancer and COPD. We calculated tests of significance and confidence intervals (95% CIs) based on the Poisson distribution ([@b25-ehp0114-001293]). In view of the clear direction of the *a priori* hypotheses for arsenic and both malignant and nonmalignant pulmonary diseases, we conducted one-tailed tests of significance for increases in these outcomes. We assessed tests for effect modification by age group (comparing 30--39 and 40--49 year age groups) and tests for effect modification by sex and for differences between those born in 1950--1957 and 1958--1970 by testing the pertinent Poisson regression interaction terms with two-tailed tests.

Results
=======

SMRs for lung cancer and COPD are given in [Table 1](#t1-ehp0114-001293){ref-type="table"} for the 30--39 and 40--49 age groups separately and combined and for men and women separately and combined. Based on the Poisson regression interaction terms, there was no evidence of differences in rate ratios between 30--39 and 40--49 age groups for lung cancer and COPD causes of death, so we focused on the SMRs for the overall age range 30--49 years. For lung cancer, the SMR for 30--49 years of age was increased for those born in the period 1950--1957 for both men (SMR = 8.2; 95% CI, 6.2--10.8, *p* \< 0.001) and women (SMR = 4.7; 95% CI, 2.7--7.7; *p* \< 0.001). The lung cancer SMR was also increased for those born in 1958--1970 (women: SMR = 2.9; 95% CI, 0.6--8.5; *p* = 0.087; men: SMR = 8.1; 95% CI, 4.3--13.9; *p* \< 0.001). Concerning COPD mortality, bronchiectasis SMRs were markedly increased for both men and women, especially for those born in the high-exposure period 1958--1970 (women: SMR = 50.1; 95% CI, 20.0--103; *p* \< 0.001; men: SMR = 36.4; 95% CI, 4.1--132; *p* = 0.001). SMRs for other COPD causes of death excluding bronchiectasis were elevated, but much less than for bronchiectasis. Finally, for all other causes of death combined, there was little evidence of increased mortality for either birth cohort, as shown in [Table 1](#t1-ehp0114-001293){ref-type="table"}.

The lung cancer relative risks are higher for men than for women, but the CIs for women are wide because of the relatively small numbers and overlap the lung cancer SMR for men (point estimate for men 30--49 years of age, 8.1; 95% CI for women, 0.6--8.5; [Table 1](#t1-ehp0114-001293){ref-type="table"}). Testing Poisson regression interaction terms, there was little evidence of effect modification by sex for the period 1950--1957 (*p* = 0.23), but testing for effect modification for those born in the period 1958--1970 yields a *p*-value of 0.04, with higher relative risks for men than for women (8.1 for men and 2.9 for women). The pooled results are presented in [Table 1](#t1-ehp0114-001293){ref-type="table"} and [Figure 2](#f2-ehp0114-001293){ref-type="fig"}. They show that lung cancer rates are greatly increased for both those born in 1950--1957 with childhood exposure and for those born in 1958--1970 who would have experienced *in utero* exposure. However, for bronchiectasis, and to a lesser extent for other COPD mortality, the SMRs are much higher for those born in 1958--1970 (SMR = 46.2; 95% CI, 21.1--87.7; *p* \< 0.001) than for those born in 1950--1957 before the very high exposures started (SMR = 12.4; 95% CI, 3.3--31.7; *p* \< 0.001; Poisson regression test for difference in bronchiectasis rate ratios for the two periods, *p* = 0.02).

Discussion
==========

Region II of Chile provides a unique opportunity to investigate arsenic health effects. It is one of the driest areas of the world, and water used in major cities and towns comes from single sources with known arsenic concentration. Furthermore, there was an abrupt onset of high exposure in 1958 in Antofagasta, the major city of region II with a population at that time of about 200,000 ([@b39-ehp0114-001293]), and an abrupt reduction in exposure in 1971 when the first large arsenic removal plant in the world was installed there. Such clear-cut exposure patterns are rare in environmental epidemiology, except perhaps radiation exposure from use of the atomic bomb in Hiroshima and Nagasaki and, to a lesser extent, ionizing radiation from accidents at nuclear reactors.

The magnitude of the effects found on lung cancer and bronchiectasis mortality has no parallel with effects of other environmental exposures occurring *in utero* and/or in early childhood. No lung cancer cases were reported in 40 years among the *in utero*--exposed survivors of the atomic bombing of Hiroshima and Nagasaki ([@b38-ehp0114-001293]). Children with the highest gamma radiation exposure in Hiroshima and Nagasaki \< 10 years of age did not experience increased lung cancer risks as adults, but those exposed in the age range of 10--19 years had lung cancer relative risk estimates of about 2.5 those of young adults 30--39 years of age ([@b26-ehp0114-001293], [figure 2](#f2-ehp0114-001293){ref-type="fig"}). The evidence for an effect of childhood exposure to environmental tobacco smoke on adult lung cancer rates is mixed, with a meta-analysis finding no overall evidence of increased risks ([@b3-ehp0114-001293]). However, a prospective study reported a relative risk estimate of 3.6 (95% CI, 1.2--11.1) based on four lung cancer cases among those with "many hours" of daily exposure ([@b31-ehp0114-001293]). By contrast, we report here a total of 84 deaths from lung cancer after childhood exposure to high concentrations of arsenic in drinking water in Chile, a 6- and 7-fold increase above rates in the rest of Chile ([Table 1](#t1-ehp0114-001293){ref-type="table"}).

Some supportive evidence provides biologic plausibility for arsenic having effects *in utero*. Arsenic crosses the placenta in animals and humans, and there is human evidence that arsenic is a developmental toxicant affecting birth weight and reproductive outcomes ([@b8-ehp0114-001293]; [@b13-ehp0114-001293]; [@b14-ehp0114-001293]; [@b17-ehp0114-001293], [@b16-ehp0114-001293]). A study conducted in Bangladesh showed an increased risk for stillbirth \[odds ratio (OR) = 2.5; 95% CI, 1.5--4.9\] and spontaneous abortion (OR = 2.5; 95% CI, 1.5--4.3) in women with current arsenic exposure ≥ 100 μg/L in water ([@b21-ehp0114-001293]), and a study in West Bengal found increased risks of stillbirths (OR = 6.1; 95% CI, 1.5--24.0) ([@b32-ehp0114-001293]). As a whole, these epidemiologic data provide evidence that arsenic exposure *in utero* could be associated with a number of adverse effects. The present study, however, is the first to provide evidence that early-life exposures may produce effects manifesting in adults.

Oral-dose animal studies demonstrate arsenic teratogenicity ([@b4-ehp0114-001293]; [@b30-ehp0114-001293]). Of particular relevance to our study is evidence that arsenic is a transplacental carcinogen in mice ([@b34-ehp0114-001293]). Female offspring of pregnant mice that were given high doses of arsenic in their drinking water developed tumors at multiple sites, including the lung, with lung carcinoma increased to 5 of 24 (21%) compared with 0 of 25 (0%) in the unexposed controls.

Strengths of our study include the extensive documentation of arsenic in drinking water in the Antofagasta water system. Records of arsenic levels in Antofagasta have been kept for the last 50 years, and almost all residents drink from the same water supply. One potential limitation of this study is that it is ecologic in nature, because overall mortality rates in the cities of Antofagasta/Mejillones were compared with those of the rest of Chile. Residence was determined from death certificates and relates to residence at the time at death. We cannot be certain that those manifesting the increased mortality were actually born in Antofagasta/Mejillones. However, the increases in relative risks are far too great to result from bias due to in-migration of very high-risk persons born elsewhere. We conclude that the effects are most probably due to arsenic in the water and that, if anything, they are diluted by in-migration of people who were born and grew up elsewhere in Chile.

The study's weakness lies in its reliance on death certificates, even though Chilean mortality records are well documented: Laws require that deaths be registered with the Civilian Registration Service (Servicio de Registro Civil), whereas another branch of government, the National Institute of Statistics (Instituto Nacional de Estadísticas), oversees validation of the generated data. Death certificates are coded according to the standard ICD, and the 1996 World Health Statistics cited Chile as having 100, 100, and 98% of all estimated deaths registered for the years 1991, 1993, and 1994, respectively ([@b36-ehp0114-001293]). However, although death certificates provide reasonably good data for lung cancer studies, they have known limitations for identifying death from chronic respiratory disease ([@b24-ehp0114-001293]). This leads one to question whether medical practices in region II might have led to overdiagnosis of chronic respiratory disease as a cause of death placed on death certificates, particularly deaths from bronchiectasis. However, separating out the findings concerning bronchiectasis from other COPD causes of death was conducted with a clear *a priori* hypothesis. Although previous mention had been made in the literature of bronchiectasis and arsenic, it was the recent finding of a 10-fold increase in bronchiectasis prevalence in persons with high exposure to arsenic and arsenic-caused skin lesions in West Bengal, India ([@b12-ehp0114-001293]), that led us specifically to evaluate bronchiectasis in this study.

Although smoking is strongly associated with mortality from lung cancer and COPD, confounding due to smoking is unlikely. Smoking is not a strong risk factor for bronchiectasis and so would not confound our findings regarding this disease ([@b2-ehp0114-001293]). And even in extreme form, confounding could not produce the marked elevation of lung cancer relative risks we have found ([@b1-ehp0114-001293]). In addition, smoking data do not indicate higher smoking rates in region II than in the rest of Chile, according to a national survey conducted in 1990 ([@b22-ehp0114-001293]). The survey included the two largest cities in region II (Antofagasta and Calama), which constitute 80% of the region II population; the proportion of smokers in these two cities was found to be lower than the rest of Chile, and the two cities also had a smaller proportion of people who smoked more than one pack per day ([Table 2](#t2-ehp0114-001293){ref-type="table"}) ([@b27-ehp0114-001293]). Although there is some evidence that exposure of children to passive smoking in their homes increases the risk of adult lung cancer ([@b19-ehp0114-001293]; [@b31-ehp0114-001293]), an earlier meta-analysis estimated the relative risk to be 0.91 (95% CI, 0.8--1.05) ([@b3-ehp0114-001293]). Even if passive smoking does increase the risk of adult lung cancer, such exposure occurs throughout Chile. Finally, occupational exposures to arsenic, such as in the mining and refining of copper, could contribute to COPD and lung cancer mortality, but these occupational exposures mainly involve men, and our study found similar increases in mortality in both men and women.

In conclusion, we have demonstrated pronounced increases in mortality from lung cancer and bronchiectasis in persons with probable exposure to high concentrations of arsenic in drinking water *in utero* and early childhood. These findings are important in that they provide some of the first human evidence of effects from environmental exposures to toxic chemicals *in utero* and early childhood resulting in disease in adults. A marked increase in mortality in young adults is also of public health importance and should be taken into consideration in setting arsenic drinking water standards.
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###### 

SMRs for bronchiectasis, other COPD, all other deaths, and lung cancer for Antofagasta/Mejillones, for ages 30--49, for men and women both separately and pooled.

                                       Born 1950--1957   Born 1958--1970                                                                    
  -------- -------- ------------------ ----------------- ----------------- ------------------ ---------- ----- -------- ------------------- ----------
  30--39   Male     Lung cancer        15                1.17              12.8 (7.1--21.1)   \< 0.001   12    1.30     9.2 (4.8--16.1)     \< 0.001
                    Bronchiectasis     3                 0.15              19.4 (4.0--56.8)   0.001      2     0.05     36.4 (4.1--132)     0.001
                    Other COPD         1                 0.21              4.7 (0.1--26.0)    0.193      1     0.46     2.2 (0.1--12.1)     0.368
                    All other deaths   129               155.78            0.8 (0.7--1.0)     0.987      305   304.41   1.0 (0.9--1.1)      0.494
  30--39   Female   Lung cancer        2                 0.48              4.2 (0.5--15.1)    0.084      3     0.83     3.6 (0.7--10.5)     0.052
                    Bronchiectasis     0                 0.04              0                  ---        6     0.14     42.9 (15.7--93.4)   \< 0.001
                    Other COPD         2                 0.14              13.9 (1.7--50.2)   0.009      4     0.33     12.2 (3.3--31.2)    \< 0.001
                    All other deaths   74                64.95             1.1 (0.9--1.4)     0.145      145   113.73   1.3 (1.1--1.5)      0.003
  30--39   Pooled   Lung cancer        17                1.65              10.3 (6.0--16.5)   \< 0.001   15    2.14     7.0 (3.9--11.6)     \< 0.001
                    Bronchiectasis     3                 0.19              15.8 (3.2--46.0)   0.001      8     0.19     41.1 (17.7--80.9)   \< 0.001
                    Other COPD         3                 0.36              8.4 (1.7--24.5)    0.006      5     0.79     6.3 (2.1--14.8)     0.001
                    All other deaths   203               220.73            0.9 (0.8--1.1)     0.891      450   418.14   1.1 (1.0--1.2)      0.064
  40--49   Male     Lung cancer        37                5.14              7.2 (5.1--9.9)     \< 0.001   1     0.29     3.4 (0.01--18.9)    0.255
                    Bronchiectasis     0                 0.10              0                  ---        0     0        0                   ---
                    Other COPD         3                 1.30              2.3 (0.5--6.7)     0.144      1     0.10     10.2 (0.3--56.8)    0.093
                    All other deaths   270               292.37            0.9 (0.8--1.0)     0.911      21    19.66    1.1 (0.7--1.6)      0.411
  40--49   Female   Lung cancer        14                2.90              4.8 (2.6--8.1)     \< 0.001   0     0.20     0.0                 ---
                    Bronchiectasis     1                 0.04              27.6 (0.7--154)    0.036      1     0.0      0.0                 ---
                    Other COPD         2                 0.76              2.6 (0.3--9.5)     0.177      1     0.04     27.4 (0.7--153)     0.036
                    All other deaths   178               147.78            1.2 (1.0--1.4)     0.009      17    11.92    1.4 (0.8--2.3)      0.097
  40--49   Pooled   Lung cancer        51                8.04              6.3 (4.7--8.3)     \< 0.001   1     0.50     2.0 (0.01--11.2)    0.391
                    Bronchiectasis     1                 0.13              7.5 (0.2--42.0)    0.124      1     0.0      0.0                 ---
                    Other COPD         5                 2.06              2.4 (0.8--5.7)     0.059      2     0.13     14.9 (1.8--53.7)    0.008
                    All other deaths   448               440.15            1.0 (0.9--1.1)     0.361      38    31.58    1.2 (0.9--1.7)      0.146
  30--49   Male     Lung cancer        52                6.31              8.2 (6.2--10.8)    \< 0.001   13    1.60     8.1 (4.3--13.9)     \< 0.001
                    Bronchiectasis     3                 0.25              12.0 (2.4--34.9)   0.002      2     0.05     36.4 (4.1--132)     0.001
                    Other COPD         4                 1.52              2.6 (0.7--6.7)     0.068      2     0.56     3.6 (0.4--12.9)     0.108
                    All other deaths   399               448.15            0.9 (0.8--1.0)     0.991      326   324.07   1.0 (0.9--1.1)      0.465
  30--49   Female   Lung cancer        16                3.38              4.7 (2.7--7.7)     \< 0.001   3     1.03     2.9 (0.6--8.5)      0.087
                    Bronchiectasis     1                 0.07              13.9 (0.2--77.1)   0.070      7     0.14     50.1 (20.0--103)    \< 0.001
                    Other COPD         4                 0.90              4.4 (1.2--11.3)    0.014      5     0.37     13.7 (4.4--32)      \< 0.001
                    All other deaths   252               212.73            1.2 (1.0--1.3)     0.005      162   125.64   1.3 (1.1--1.5)      0.001
  30--49   Pooled   Lung cancer        68                9.69              7.0 (5.4--8.9)     \< 0.001   16    2.63     6.1 (3.5--9.9)      \< 0.001
                    Bronchiectasis     4                 0.32              12.4 (3.3--31.7)   \< 0.001   9     0.19     46.2 (21.1--87.7)   \< 0.001
                    Other COPD         8                 2.42              3.3 (1.4--6.5)     0.004      7     0.92     7.6 (3--15.6)       \< 0.001
                    All other deaths   651               660.88            1.0 (0.9--1.1)     0.655      488   449.71   1.1 (1.0--1.2)      0.039

Abbreviations: E, expected; O, observed.

###### 

Smoking habits among men and women in the two major cities in region II in 1990 compared with data for the rest of Chile \[no. (%)\].

                                     Smoking habits (cigarettes/day)                                                                   
  --------------- ------------------ --------------------------------- ---------------- --------------- --------------- -------------- -----------------
  Antofagasta     163,500 (76.4)     13,223 (6.2)                      27,445 (12.8)    7,845 (3.7)     1,800 (0.8)     270 (0.1)      214,083 (100)
  Calama          92,214 (80.4)      8,268 (7.2)                       10,944 (9.5)     1,788 (1.6)     1,233 (1.1)     222 (0.2)      114,669 (100)
  Rest of Chile   5,443,466 (75.1)   581,686 (8.0)                     837,878 (11.6)   228,617 (3.2)   109,421 (1.5)   46,215 (0.6)   7,247,283 (100)

Data were obtained from the [@b22-ehp0114-001293].
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